Inovio Pharmaceuticals (NASDAQ:INO) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.99 and traded as high as $2.34. Inovio Pharmaceuticals shares last traded at $2.33, with a volume of 627,880 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on INO. Zacks Research cut Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a report on Wednesday, October 8th. Piper Sandler initiated coverage on Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They issued an “overweight” rating and a $5.00 target price on the stock. Finally, HC Wainwright reissued a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.80.

Inovio Pharmaceuticals Stock Up 3.6%

The business has a 50-day moving average price of $2.39 and a two-hundred day moving average price of $1.99. The firm has a market cap of $123.82 million, a PE ratio of -0.89 and a beta of 1.65.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.02. On average, equities research analysts predict that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Large investors have recently modified their holdings of the stock. Nuveen LLC purchased a new stake in shares of Inovio Pharmaceuticals during the first quarter worth $168,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Inovio Pharmaceuticals during the first quarter worth $90,000. Bank of New York Mellon Corp increased its position in shares of Inovio Pharmaceuticals by 22.4% during the first quarter. Bank of New York Mellon Corp now owns 75,422 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 13,784 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Inovio Pharmaceuticals by 38.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 27,429 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in Inovio Pharmaceuticals by 26.7% in the first quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 13,939 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.